3. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 69: 1237–1245. 4. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860. 5. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299. 6. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1: 20–26. 7. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25–37. 8. Pfeifer GP, Besaratinia A (2009) Mutational spectra of human cancer. Hum Genet 125: 493–506. 9. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985–991. 10. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, et al. (2002) Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346: 420–427. 11. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, et al. (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23: 7518–7528. 12. Wang J, He X, Luo Y, Yarbrough WG (2006) A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochem J 393: 489–501. 13. Jiang H, Luo S, Li H (2005) Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. J Biol Chem 280: 20651–20659. 14. Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, et al. (2011) Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res 71: 2949–2958. 15. Rousset R, Fabre S, Desbois C, Bantignies F, Jalinot P (1998) The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene 16: 643–654. 16. Alewine C, Olsen O, Wade JB, Welling PA (2006) TIP-1 Has PDZ Scaffold Antagonist Activity. Mol Biol Cell 17: 4200–4211. 17. Kanamori M, Sandy P, Marzinotto S, Benetti R, Kai C, et al. (2003) The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells. J Biol Chem 278: 38758–38764. 18. Besser J, Leito JT, van der Meer DL, Bagowski CP (2007) Tip-1 induces filopodia growth and is important for gastrulation movements during zebrafish development. Dev Growth Differ 49: 205–214. 19. Hampson L, Li C, Oliver AW, Kitchener HC, Hampson IN (2004) The PDZ protein Tip-1 is a gain of function target of the HPV16 E6 oncoprotein. Int J Oncol 25: 1249–1256. 20. Reynaud C, Fabre S, Jalinot P (2000) The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is involved in Rho signaling to the serum response element. J Biol Chem 275: 33962–33968. 21. Zencir S, Ovee M, Dobson MJ, Banerjee M, Topcu Z, et al. (2011) Identification of brain-specific angiogenesis inhibitor 2 as an interaction partner of glutaminase interacting protein. Biochem Biophys Res Commun 411: 792– 797. TIP-1 and Radioresistance of Malignant Gliomas 22. Oliver AW, He X, Borthwick K, Donne AJ, Hampson L, et al. (2011) The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16, which activates Cdc42. Br J Cancer 104: 324–331. 23. van Ham M, Hendriks W (2003) PDZ domains-glue and guide. Mol Biol Rep 30: 69–82. 24. Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H (2005) PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics 21: 827–828. 25. Wang H, Yan H, Fu A, Han M, Hallahan D, et al. (2010) TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation. PLoS One 5: e12051. 26. Han M, Wang H, Zhang HT, Han Z (2012) The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice. Biochem Biophys Res Commun 422: 139–145. 27. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, et al. (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84: 7413–7417. 28. Feng Z, Kachnic L, Zhang J, Powell SN, Xia F (2004) DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 279: 28574–28584. 29. Rothkamm K, Burdak-Rothkamm S (2011) Ionizing radiation-induced DNA strand breaks and gamma-H2AXgamma-H2AX foci in cells exposed to nitric oxide. Methods Mol Biol 704: 17–25. 30. Furukawa M, Zhang Y, McCarville J, Ohta T, Xiong Y (2000) The CUL1 C- terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1. Mol Cell Biol 20: 8185–8197. 31. Han Z, Fu A, Wang H, Diaz R, Geng L, et al. (2008) Noninvasive assessment of cancer response to therapy. Nat Med 14: 343–349. 32. Network CGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068. 33. Morris EJ, Dreixler JC, Cheng KY, Wilson PM, Gin RM, et al. (1999) Optimization of single-cell gel electrophoresis (SCGE) for quantitative analysis of neuronal DNA damage. Biotechniques 26: 282–283, 286–289. 34. Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG (2007) LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 12: 239– 251. 35. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979–987. 36. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734–36741. 37. Banerjee M, Huang C, Marquez J, Mohanty S (2008) Probing the structure and function of human glutaminase-interacting protein: a possible target for drug design. Biochemistry 47: 9208–9219. 38. Alewine C, Kim BY, Hegde V, Welling PA (2007) Lin-7 targets the Kir 2.3 channel on the basolateral membrane via a L27 domain interaction with CASK. Am J Physiol Cell Physiol 293: C1733–1741. 39. Zhang J, Yan X, Shi C, Yang X, Guo Y, et al. (2008) Structural basis of beta- catenin recognition by Tax-interacting protein-1. J Mol Biol 384: 255–263. 40. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844–848. PLOS ONE | www.plosone.org 13 September 2012 | Volume 7 | Issue 9 | e45402